| Name | Title | Contact Details |
|---|
CinCor is a clinical-stage biopharmaceutical company targeting cardiovascular, metabolic and kidney diseases.
We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients lives.
Eyenovia is a clinical stage, biopharmaceutical company transforming the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia`s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics.
Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective.
PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology.